Panel discussion
Deloitte AG
| Country: | Switzerland |
| Website: | https://www2.deloitte.com/ch/en/events/2023/swiss-biotech-day.html |
| Date: | April 24, 2023 |
| Time: | 14:45 – 15:30 |
| Room: | Marriott Hotel |
Panel title
How to Scale for Growth: How to succeed in navigating key milestones such as funding, IPO, operational setup, and launch, which will define your future
Panel summary
This panel provides a cross-functional perspective from biotech industry leaders who will share their experiences in navigating key growth milestones along their journey. You will hear leading biotech C-suite executives and investor explaining how they addressed key strategic questions such as:
- How do I execute on the science and raise sufficient funds?
- What are criteria investors value to make funding decisions?
- What are the attributes of a viable business model and key partnerships needed?
- What are the key commercial, regulatory, and quality decisions needed to support our first launch?
- What is our commercial and operational model to support growth?
Speaker information
Moderation
Elisabeth Aloy, PhD, Life Sciences Strategy Partner at Deloitte and leader of the small and mid-cap market segment in Switzerland
Panelists
Melanie Rolli, CEO of Helsinn and Board Member, leader with strong expertise in global drug development for different therapeutic areas incl. HIV, dermatology and oncology for 20 years , formerly serving as CEO of AELIX Therapeutics and PIQUR Therapeutics and in management roles at Novartis
Boris Javelle, CFO, early stage Biotech & held VP/SVP positions, for small Cap’ companies including Nektar, BluePrint, Tesaro, Cubist & Intermune.
Peter Vanovertveld, is co-CEO at Smart Reporting, a leading health-tech innovator; Peter previously led Global Patient Access at Vifor Pharma and Baxalta, and worked as public affairs advisor with United Nations Organization and European Union institutions
Klaus Breiner, Founding partner of Pureos; has been a venture capital investor since 2001, across different regions, companies, stages and types. Klaus invested in AM-Pharma, Alpex Pharma, Cadence Pharmaceuticals, Glycart Biotechnology, Hummingbird Bioscience, ImCheck Therapeutics and Vaximm
Company profile
Deloitte helps businesses balance patient demands, market potential, and policy compliance in the rapidly transforming life sciences and health care industry. Deloitte will guide you through key stages and considerations, from tax and legal setup to commercial launch and beyond. Deloitte offers solutions to stay competitive and have the skills, tools, and multi-disciplinary solutions to solve complex problems.
